Interconnection of Differentiated Thyroid Cancer and Cardiovascular Disease: Insulin Resistance as a Potential Molecular Link—A Proposed Mechanism - Scorecard - MDSpire

Interconnection of Differentiated Thyroid Cancer and Cardiovascular Disease: Insulin Resistance as a Potential Molecular Link—A Proposed Mechanism

  • By

  • Guizhang Hou

  • Tianshu Gao

  • April 22, 2026

  • 0 min

Share

Clinical Scorecard: Interconnection of Differentiated Thyroid Cancer and Cardiovascular Disease: Insulin Resistance as a Potential Molecular Link—A Proposed Mechanism

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationLong-term survivors of differentiated thyroid cancer
Care Setting

Key Highlights

  • Direct clinical evidence linking DTC to systemic insulin resistance is limited.

Guideline-Based Recommendations

Diagnosis

    Management

    • Consider metabolic factors, including insulin resistance, in the management of DTC patients.
    • Assess metabolic health regularly in DTC patients.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Patients diagnosed with differentiated thyroid cancer

        Insulin resistance and metabolic health should be considered in treatment planning.

        Clinical Best Practices

        • Integrate cardio-oncologic risk stratification in DTC management, particularly regarding TSH suppression therapy.

        References

        Original Source(s)

        Interconnection of Differentiated Thyroid Cancer and Cardiovascular Disease: Insulin Resistance as a Potential Molecular Link—A Proposed Mechanism

        • by Guizhang Hou, Tianshu Gao

        • April 22, 2026

        Related Content

        Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

        Differentiation of hepatocellular carcinoma from hepatic hemangioma using diffusion-derived vessel density map-based radiomics features

        Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma